Strategic Transformation Supports Roquette’s H1 2026 Performance

Lille – September 24^th, 2026 – Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, today announced its H1 2026 results, following the approval of its financial statements by the Board of Directors.

• +9% turnover growth to €2,586 million and +18% Current EBITDA increase to €337 million. Performance was supported by favorable volume and mix effects, the continued contribution of an enhanced portfolio, and the first positive results from Shift & Lead, which is already delivering ahead of target.
  • Sales of cellulose and alginates for pharmaceutical and healthcare applications supported performance, despite ongoing challenging market conditions in the starch industry. 
  • The strategic ramp-up in proteins and fibers for the food and nutrition business continues to develop in line with expectations.
  • Strong commercial performance in India and China, two key strategic markets for Roquette.
• +101 bps increase in Current EBITDA margin to 13.0%, driven by pharma, food and nutrition segments and disciplined cost management.
• Free Cash-Flow improved to -€54 million, to be compared with -€150 million in H1 2025 (excluding the cash impact of the IFF Pharma Solutions acquisition).
• Successful issuance of €600 million of perpetual hybrid bonds¹  in April 2026 to further strengthen Roquette’s financial position. 
   

Thierry Fournier, CEO of Roquette, commented: “In a market environment that remains challenging, dynamic and competitive, Roquette’s performance was supported by the contribution of new product lines, especially in the pharma and healthcare segment. While like-for-like performance remains impacted by the aforementioned market conditions, we are encouraged by the early progress of Shift & Lead, the company’s strategic plan, which is helping us to position the Group for long-term growth.” 

Cellulose and Alginates Drive HPS’ Performance

Within the Health & Pharma Business Unit, the starch and capsules businesses continued to face headwinds from ongoing competition and price pressure. This was partially offset by the contribution of Roquette’s cellulose and alginates product lines which delivered strong performance in H1 2026. This reflects the relevance of the company’s strategy to expand its portfolio and develop value-added solutions that address evolving customer and patient needs. 

Proteins and Fibers Support NBI’s Strategic Growth Ambitions

Despite persistent market headwinds affecting the Nutrition & Bioindustry Business Unit, Roquette’s proteins and fibers businesses continued to develop in line with expectations, with strong momentum in Europe and North America. The proteins business recorded growth in volumes and sales compared to the first half of 2025, reflecting the execution of Roquette’s ambition to become a reference in high-value pea ingredients. More broadly across the Business Unit, performance was especially strong across Asia, where progress in India continued alongside sustained momentum throughout the region. 

Shift & Lead Delivering Early Results

In early 2026, Roquette launched Shift & Lead, the Group's strategic transformation plan designed to strengthen competitiveness, accelerate performance and support long-term value creation.

“In an evolving and demanding market environment, we recognized the need to act decisively and responsibly.  This is why we launched Shift & Lead: to ensure Roquette remains well positioned for the future while continuing to create value for customers, employees, partners and shareholders. I have been impressed by the speed and commitment of our teams in bringing this plan to life – it has already delivered more than €60m in just a few months. Across the Group, we are fostering new ways of thinking and working, with a clear focus on operational excellence, agility and performance. We remain confident in our ability to capture future opportunities and build on the strengths that have long defined Roquette,” concluded Thierry Fournier. 

1. Press Release: Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros
 

Download the full press release below.